121 related articles for article (PubMed ID: 23742937)
1. Recognition of intermolecular G-quadruplexes by full length nucleophosmin. Effect of a leukaemia-associated mutation.
Bañuelos S; Lectez B; Taneva SG; Ormaza G; Alonso-Mariño M; Calle X; Urbaneja MA
FEBS Lett; 2013 Jul; 587(14):2254-9. PubMed ID: 23742937
[TBL] [Abstract][Full Text] [Related]
2. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
3. Nucleophosmin in leukemia: Consequences of anchor loss.
Brodská B; Šašinková M; Kuželová K
Int J Biochem Cell Biol; 2019 Jun; 111():52-62. PubMed ID: 31009764
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
Falini B; Mecucci C; Tiacci E; Alcalay M; Rosati R; Pasqualucci L; La Starza R; Diverio D; Colombo E; Santucci A; Bigerna B; Pacini R; Pucciarini A; Liso A; Vignetti M; Fazi P; Meani N; Pettirossi V; Saglio G; Mandelli F; Lo-Coco F; Pelicci PG; Martelli MF;
N Engl J Med; 2005 Jan; 352(3):254-66. PubMed ID: 15659725
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
6. AML-associated mutation of nucleophosmin compromises its interaction with nucleolin.
Šašinková M; Holoubek A; Otevřelová P; Kuželová K; Brodská B
Int J Biochem Cell Biol; 2018 Oct; 103():65-73. PubMed ID: 30130654
[TBL] [Abstract][Full Text] [Related]
7. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants.
Bolli N; Nicoletti I; De Marco MF; Bigerna B; Pucciarini A; Mannucci R; Martelli MP; Liso A; Mecucci C; Fabbiano F; Martelli MF; Henderson BR; Falini B
Cancer Res; 2007 Jul; 67(13):6230-7. PubMed ID: 17616680
[TBL] [Abstract][Full Text] [Related]
8. Leukemia-Associated Mutations in Nucleophosmin Alter Recognition by CRM1: Molecular Basis of Aberrant Transport.
Arregi I; Falces J; Olazabal-Herrero A; Alonso-Mariño M; Taneva SG; Rodríguez JA; Urbaneja MA; Bañuelos S
PLoS One; 2015; 10(6):e0130610. PubMed ID: 26091065
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
[TBL] [Abstract][Full Text] [Related]
10. Localization of AML-related nucleophosmin mutant depends on its subtype and is highly affected by its interaction with wild-type NPM.
Brodská B; Kráčmarová M; Holoubek A; Kuželová K
PLoS One; 2017; 12(4):e0175175. PubMed ID: 28384310
[TBL] [Abstract][Full Text] [Related]
11. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.
Federici L; Falini B
Protein Sci; 2013 May; 22(5):545-56. PubMed ID: 23436734
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
13. Role of nucleophosmin in acute myeloid leukemia.
Meani N; Alcalay M
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1283-94. PubMed ID: 19761432
[TBL] [Abstract][Full Text] [Related]
14. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemical demonstration of mutant nucleophosmin in acute myeloid leukemia: biological and clinical features related to NPMc expression].
Bedekovics J; Rejto L; Telek B; Udvardy M; Ujfalusi A; Oláh E; Hevessy Z; Kappelmayer J; Kajtár B; Méhes G
Orv Hetil; 2009 May; 150(22):1031-5. PubMed ID: 19465351
[TBL] [Abstract][Full Text] [Related]
17. Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.
Kuželová K; Brodská B; Fuchs O; Dobrovolná M; Soukup P; Cetkovský P
PLoS One; 2015; 10(5):e0127637. PubMed ID: 25992555
[TBL] [Abstract][Full Text] [Related]
18. [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes].
Zhang Y; Zhang MR; Yang L; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):470-3. PubMed ID: 17147251
[TBL] [Abstract][Full Text] [Related]
19. Two novel NPM1 mutations in a therapy-responder AML patient.
Pianta A; Fabbro D; Damiani D; Tiribelli M; Fanin R; Franzoni A; Romanello M; Tell G; Di Loreto C; Damante G
Hematol Oncol; 2010 Sep; 28(3):151-5. PubMed ID: 19593743
[TBL] [Abstract][Full Text] [Related]
20. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
Quentmeier H; Martelli MP; Dirks WG; Bolli N; Liso A; Macleod RA; Nicoletti I; Mannucci R; Pucciarini A; Bigerna B; Martelli MF; Mecucci C; Drexler HG; Falini B
Leukemia; 2005 Oct; 19(10):1760-7. PubMed ID: 16079892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
